Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation”) (TSX VENTURE:TBP) (TBPMF), wishes to clarify that the annual general meeting of shareholders of the Corporation (the “Meeting”) is to be held in the City of Montréal, Québec. The Corporation noted that the notice of meeting and record date filed under the Corporation’s profile on SEDAR on April 27, 2018 incorrectly stated that the Meeting would be held in the City of Ottawa, Ontario. The time and date of the Meeting are unchanged and it is scheduled to be held on June 19, at 2:00 p.m.
The Meeting will be held at the offices of Stikeman Elliott LLP located at:
1155, René-Lévesque Boulevard West,
Shareholders as of the record date of May 15, 2018, will receive an information circular and proxy voting instruction form by mail in advance of the Meeting.
The Corporation has filed an amended notice of meeting and record date on SEDAR and shareholders will be able to download the amended notice of meeting and record date.
The Corporation apologizes for any confusion.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TBP.V) (TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a clinical program aimed at bringing novel drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries that are engaged in the development of Bio Pharmaceuticals and Natural Health Products containing cannabis and other medicinal plant-based elements. Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.